Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUKNQ5)

Drug Name

AZD8330 Drug Info

Synonyms

AZD8330; 869357-68-6; AZD-8330; ARRY-424704; ARRY-704; UNII-G4990BOZ66; AZD 8330; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; G4990BOZ66; C16H17FIN3O4; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; RWEVIPRMPFNTLO-UHFFFAOYSA-N

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 16666708
ChEBI ID: CHEBI:91424
CAS Number: CAS 869357-68-6
TTD Drug ID: DMUKNQ5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting MAPK/ERK kinase kinase (MAP3K)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-162	DM1P6FR	Melanoma	2C30	Approved	[2]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[3]
BAY 86-9766	DMPW5SB	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
Selumetinib	DMC7W6R	Neurofibromatosis type 1	LD2D.10	Phase 3	[5]
MSC1936369B	DMH1DYU	Colorectal cancer	2B91.Z	Phase 2	[6]
RO-5126766	DM3U9BY	Non-small-cell lung cancer	2C25	Phase 2	[7]
E6201	DMOSL9P	Psoriasis vulgaris	EA90	Phase 2	[8]
PD-0325901	DM27D4J	Breast cancer	2C60-2C65	Phase 2	[2]
WX-554	DMRABOS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MAPK/ERK kinase kinase (MAP3K)	TTROQ37	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8474).
2	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
3	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
4	RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47.
5	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59.
6	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101.
7	The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
8	E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31.
9	Clinical pipeline report, company report or official report of Roche.